GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cronos Group Inc (NAS:CRON) » Definitions » Growth Rank
中文

Cronos Group (Cronos Group) Growth Rank : 8 (As of Apr. 25, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Cronos Group Growth Rank?

Cronos Group has the Growth Rank of 8.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.


Competitive Comparison of Cronos Group's Growth Rank

For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cronos Group's Growth Rank Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cronos Group's Growth Rank distribution charts can be found below:

* The bar in red indicates where Cronos Group's Growth Rank falls into.



Cronos Group Growth Rank Related Terms

Thank you for viewing the detailed overview of Cronos Group's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Cronos Group (Cronos Group) Business Description

Traded in Other Exchanges
Address
111 Peter Street, Suite 300, Toronto, ON, CAN, M5V 2H1
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S. the company has an option to acquire 10.5% of U.S. multistate operator PharmaCann upon easing of federal prohibition.
Executives
Kamran Khan director 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Elizabeth Seegar director 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Dominik Meier director 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Jason Marc Adler director 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2G9
Mcginness James Andrew Iii officer: VP, Controller C/O MARKETWISE, 1125 N. CHARLES STREET, BALTIMORE MD 21201
Maple Holdco (bermuda) Ltd. 10 percent owner C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Maple Acquireco (canada) Ulc 10 percent owner C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Altria Summit Llc 10 percent owner C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Altria Group, Inc. 10 percent owner 6601 WEST BROAD STREET, RICHMOND VA 23230
James Holm officer: Chief Financial Officer 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Arye Weigensberg officer: See Remarks 111 PETER STREET, SUITE 300, TORONTO A6 MV5 2H1
Doucet Terrence Gregory Joseph officer: See Remarks 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
John Griese officer: See Remarks 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Ran Gorelik officer: General Manager (Israel) 111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Robert L Madore officer: Chief Financial Officer C/O RALPH LAUREN CORPORATION, 650 MADISON AVENUE, NEW YORK NY 10022